The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | January 9, 2008 | ||||
| Last Updated Date | December 2, 2009 | ||||
| Start Date ICMJE | March 2004 | ||||
| Primary Completion Date | December 2009 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Pts w/suspected lung lesions will undergo more breath-hold CT scan & if visible lesion(s), gated-PET will be acquired plus clinical PET/CT. Scans will be used to compare how often additional lung lesions can be identified on breath-hold CT, if lesions [ Time Frame: 5 years ] [ Designated as safety issue: No ] | ||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00598065 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules | ||||
| Official Title ICMJE | The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules | ||||
| Brief Summary | The purpose of this study is to see if researchers can improve the detection of lung cancer by using a new method which will help us to take multiple snapshot images of the lungs while the patient is breathing. We are also investigating whether with the help of this new method we can better measure the actual amount of radioactivity that is taken up by the cancer. The name of this new method is respiratory gated PET/CT. Previous research has shown that PET scans may be useful in investigating whether cancer has spread to other parts of the lung or body. Using our standard method, smaller cancers are sometimes difficult to detect in the lungs because the PET images are taken over several minutes and the patient is breathing during that time. That means the cancer may appear "blurred" on the images (like a poor photograph) or may not be identified at all. In this study, in addition to the images that were ordered by your doctor, we will take additional images of your lungs while you are following a breathing command ("breath in-hold-breath out"). We will then compare the images of your cancer during the regular PET study with those taken during the breathing commands. The hypotheses to be tested in this pilot study are:
|
||||
| Detailed Description | Positron emission tomography is now a clinically accepted imaging modality for the evaluation of pulmonary nodules as well as for the staging of patients with lung cancer. PET imaging with the radiotracer 18 Fluoro-deoxy-glucose (FDG) has a high accuracy for the differentiation between benign and malignant lung lesions and for the detection of nodal metastases. This is because malignant tumors are characterized by an increase in glucose metabolism as compared to most normal tissues. In clinical practice, PET images are interpreted visually or semiquantitatively, using a standardized uptake value (SUV). Previous studies have shown that SUV thresholds can be used with high accuracy to distinguish between benign and malignant lesions that exhibit increased uptake of FDG. In addition, the SUV is frequently used as a surrogate marker for the evaluation of a response to chemo- or radiation therapy. Unfortunately, the accuracy of SUV measurements may be affected by lesion motion during the image acquisition. This is a particular problem in PET imaging of the lung. Normal respiratory motion, and hence lesion motion, causes a smearing effect, whereby the concentration of radiotracer within a given lesion is spread out over a larger area. For the same reason small lesions and lesions with relatively low uptake of radiotracer may become undetectable during normal breathing (partial volume effect). PET images are acquired for several minutes, image acquisition during breath hold is therefore not an option for clinical scans. However recently published work from UCLA (Auerbach et al. J Nucl Med., February 2006) shows that 3 lesions per patient on average can be missed on shallow breathing scans compared to breath-hold CT scans. These lesions did not show any FDG uptake on clinical PET scans. The goal of this pilot study is to evaluate whether respiratory gating during PET image acquisition enables the detection of those lesions which are identified during the breath-hold CT scan. |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Not Provided | ||||
| Study Design ICMJE | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
||||
| Condition ICMJE | Lung Cancer | ||||
| Intervention ICMJE | Other: PET/CT
Synchronized PET/CT Imaging |
||||
| Study Arm (s) | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 26 | ||||
| Completion Date | December 2009 | ||||
| Primary Completion Date | December 2009 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years and older | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00598065 | ||||
| Other Study ID Numbers ICMJE | 04-025 | ||||
| Has Data Monitoring Committee | Yes | ||||
| Responsible Party | Schoder, Heiko, MD / Principal Investigator, Memorial Sloan-Kettering Cancer Center | ||||
| Study Sponsor ICMJE | Memorial Sloan-Kettering Cancer Center | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Memorial Sloan-Kettering Cancer Center | ||||
| Verification Date | December 2009 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||